Montelukast Can Be Prescribed to Patients with Epilepsy
Montelukast can be safely prescribed to patients with epilepsy, including those on enzyme-inducing antiepileptic drugs (AEDs), with standard dosing and no special monitoring required beyond routine clinical assessment.
Drug Interaction with Enzyme-Inducing AEDs
The FDA label explicitly addresses this concern: Phenobarbital (a potent enzyme inducer) decreases montelukast AUC by approximately 40%, but no dosage adjustment is recommended 1. The label states: "It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with SINGULAIR" 1.
This means:
- Standard montelukast doses remain appropriate even with concurrent phenobarbital, carbamazepine, or phenytoin
- The reduced montelukast levels from enzyme induction are not clinically significant enough to warrant dose increases
- Simple clinical monitoring (assessing asthma/rhinitis control) is sufficient
Standard Dosing by Age
Age-appropriate dosing 2:
- Ages 6-14 years: 5 mg chewable tablet once daily in the evening
- Ages ≥15 years and adults: 10 mg tablet once daily in the evening
- Ages 2-5 years: 4 mg chewable tablet once daily in the evening
- Ages 12-23 months: 4 mg oral granules once daily
Potential Synergistic Anticonvulsant Effect
Emerging research suggests montelukast may actually enhance anticonvulsant effects. A 2015 isobolographic study demonstrated that montelukast synergistically increases phenobarbital's anticonvulsant action against pentylenetetrazole-induced seizures, with an interaction index of 0.12 (indicating strong synergism) 3. The study showed montelukast significantly decreased phenobarbital's ED50 from 0.74 to 0.04 μmol, potentially reducing required phenobarbital doses and associated sedation 3.
A 2021 review further supports montelukast's neuroprotective and anti-oxidative activities that may reduce seizure incidence 4.
Neuropsychiatric Monitoring Considerations
While the FDA added a boxed warning for neuropsychiatric events in 2020, recent large-scale studies in children found no increased risk. A 2025 Swedish cohort study of 74,291 children (ages 6-17) found no association between montelukast use and neuropsychiatric adverse events (HR 0.99,95% CI 0.84-1.16) 5. However:
- Sleep disturbances may be more common with montelukast exposure 6, 7
- Patients should be instructed to report any neuropsychiatric symptoms (sleep problems, mood changes, agitation) 1
- This is routine clinical monitoring, not specialized testing
No Special Laboratory Monitoring Required
Unlike many AEDs, montelukast requires:
- No baseline laboratory tests
- No therapeutic drug level monitoring
- No routine liver function tests (unless hepatic insufficiency present)
- No renal dose adjustments 1
Common Pitfalls to Avoid
- Do not increase montelukast dose when co-prescribed with enzyme-inducing AEDs—the 40% reduction in exposure is not clinically significant 1
- Do not discontinue AEDs when starting montelukast—patients should maintain their seizure medications 1
- Do not use montelukast as acute seizure treatment—it is for chronic asthma/rhinitis management only
- Avoid in patients with severe hepatic impairment—pharmacokinetics have not been evaluated in this population 1
Clinical Bottom Line
Prescribe montelukast at standard age-appropriate doses to epilepsy patients without dose adjustments, even with concurrent enzyme-inducing AEDs. Monitor clinically for asthma/rhinitis control and inquire about sleep or mood changes at follow-up visits. The drug may theoretically provide additive neuroprotective benefits based on preclinical evidence.